Condition: Osteogenesis Imperfecta · Sponsor: Amgen
The primary objective of this trial is to evaluate the safety of romosozumab in participants with osteogenesis imperfecta (OI) that have completed Study 20200105, regardless of whether they received investigational product (romosozumab) until the last protocol-specified dose or ended investigational product early.
This description comes directly from the study's public registry record.
Amgen Call Center · 866-572-6436 · medinfo@amgen.com
Always discuss trial participation with your own doctor first.
| Indiana University | Indianapolis, Indiana, United States | Recruiting |
| Universitaetsklinikum Koeln | Cologne, Germany | Recruiting |
| Universitaetsklinikum Wuerzburg | Würzburg, Germany | Recruiting |
| Okayama Saiseikai Outpatient Center Hospital | Okayama, Okayama-ken, Japan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07366086